
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for NVS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Value Graph.
TapClick below to see what's inside, then upgrade to unlock for NVS and 80,000+ other tickers.
The latest quarter of the one metric Novartis AG reports, from its segment revenue to its operating figures, each with its change from the quarter before and from a year earlier, and its history back to Dec 2018.
TapClick below to see what's inside, then upgrade to unlock it for NVS and every other company we cover.
6 suppliers of Novartis AG, named in SEC filings, company releases and earnings calls, with the quote behind each one, the share of revenue where a filing gives it, and how it moved.
TapClick below to see what's inside, then upgrade to unlock it for NVS and every other company we cover.
See exactly how NVS's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NVS and 80,000+ other tickers.
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.

The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.

STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology.

Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target